Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 15/20 | 0.53 |
| ▸ | CTSL | P07711 | 8/20 | 0.53 |
| ▸ | CTSS | P25774 | 5/20 | 0.53 |
| ▸ | CTSB | P07858 | 4/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MME | P08473 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 2/20 | 0.37 |
| ▸ | MMP3 | P08254 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4896822 | 0.98 | CTSK (0.53) | CTSKCTSLCTSSCTSBPOLB | |
| SCHEMBL4907506 | 0.89 | CTSK (0.54) | CTSKCTSLCTSSCTSBPOLB | |
| SCHEMBL4908100 | 0.89 | CTSK (0.55) | CTSKCTSLCTSSCTSBPOLB | |
| SCHEMBL4904322 | 0.84 | POLB (0.43) | CTSKCTSLCTSSCTSBPOLB | |
| SCHEMBL4904858 | 0.83 | CTSK (0.58) | CTSKCTSLCTSSCTSBPOLB | |
| SCHEMBL4904566 | 0.83 | CTSS (0.54) | CTSKCTSLCTSSCTSBMEN1 | |
| SCHEMBL4907311 | 0.83 | CTSK (0.63) | CTSKCTSLCTSSCTSB | |
| SCHEMBL4905310 | 0.82 | CTSK (0.49) | CTSKCTSLCTSSCTSBPOLB | |
| SCHEMBL4910242 | 0.82 | CTSK (0.49) | CTSKCTSLCTSSCTSBPOLB | |
| SCHEMBL4896876 | 0.82 | CTSK (0.57) | CTSKCTSLCTSSCTSBPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080058333-A1 | CYCLOALKYL KETOAMIDES DERIVATIVES USEFUL AS CATHEPSIN K INHIBITORS | CATALANO JOHN G | 2008-03-06 | — | — | US | disclosed |
| US-7282512-B2 | Cycloalkyl ketoamides derivatives useful as cathepsin K inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2007-10-16 | — | — | US | disclosed |
| US-20050054819-A1 | Cycloalkyl ketoamides derivatives useful as cathepsin k inhibitors | SMITHKLINE BEECHAM CORPORATION | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054819-A1 | Cycloalkyl ketoamides derivatives useful as cathepsin k inhibitors | CTSK, CTSS, CTSE | CTSK 1/4885CTSL 12/4885CTSS 2/4885 |
| US-20080058333-A1 | CYCLOALKYL KETOAMIDES DERIVATIVES USEFUL AS CATHEPSIN K INHIBITORS | CTSK, CTSS, CTSE | CTSK 1/4885CTSL 12/4885CTSS 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.